VarmX receives Phase 1 waiver from Japanese regulator PMDA
https://www.alojapan.com/1377606/varmx-receives-phase-1-waiver-from-japanese-regulator-pmda/
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a …
https://www.alojapan.com/1377606/varmx-receives-phase-1-waiver-from-japanese-regulator-pmda/
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a …
VarmX receives Phase 1 waiver from Japanese regulator PMDA - Alo Japan All About Japan
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
www.alojapan.com
September 25, 2025 at 6:54 AM
VarmX receives Phase 1 waiver from Japanese regulator PMDA
https://www.alojapan.com/1377606/varmx-receives-phase-1-waiver-from-japanese-regulator-pmda/
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a …
https://www.alojapan.com/1377606/varmx-receives-phase-1-waiver-from-japanese-regulator-pmda/
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a …
CSL Secures Option to Acquire Dutch Blood-Clotting Drug Startup VarmX
patrickwareing.com/news/csl-sec...
patrickwareing.com/news/csl-sec...
CSL Secures Option to Acquire Dutch Blood-Clotting Drug Startup VarmX - Patrick Wareing
CSL Limited has struck a strategic collaboration and exclusive acquisition option agreement with VarmX, a Netherlands-based biotech specializing in blood
patrickwareing.com
September 17, 2025 at 4:03 PM
CSL Secures Option to Acquire Dutch Blood-Clotting Drug Startup VarmX
patrickwareing.com/news/csl-sec...
patrickwareing.com/news/csl-sec...
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment ysioscapital.com/2025/09/16/v...
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment – Ysios Capital
VarmX shareholders to receive initial $117m upfront and further potential milestone payments up to $2.1bn
ysioscapital.com
September 17, 2025 at 9:53 AM
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment ysioscapital.com/2025/09/16/v...
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com
nexttech-news.com
September 16, 2025 at 7:20 PM
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com
nexttech-news.com
September 16, 2025 at 7:20 PM
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding. Elevate your perspective with NextTech…
🧪 #Barcelona consolida su papel como hub emergente en ciencias de la vida con una operación internacional de gran impacto: Ysios Capital ha anunciado una alianza estratégica entre su participada VarmX y la farmacéutica australiana CSL
✍️ Elena Busquets
✍️ Elena Busquets
El papel de Barcelona en la macrooperación biomédica de VarmX y CSL, valorada en hasta 2.200 millones de dólares
Ysios Capital anuncia un acuerdo estratégico de desarrollo de un medicamento con opción de compra de su participada VarmX
www.thenewbarcelonapost.com
September 16, 2025 at 2:45 PM
🧪 #Barcelona consolida su papel como hub emergente en ciencias de la vida con una operación internacional de gran impacto: Ysios Capital ha anunciado una alianza estratégica entre su participada VarmX y la farmacéutica australiana CSL
✍️ Elena Busquets
✍️ Elena Busquets
EQT Life Sciences and CSL Forge a $2.2 Billion Partnership for Innovative Coagulation Treatment#None#CSL#VarmX#VMX-C001
EQT Life Sciences and CSL Forge a $2.2 Billion Partnership for Innovative Coagulation Treatment
EQT Life Sciences and CSL have entered into a strategic collaboration with VarmX, highlighting a $2.2 billion agreement for developing an innovative coagulation agent.
third-news.com
September 16, 2025 at 1:21 PM
CSL goes all in on VarmX and its coagulation-restoring therapy firstwordpharma.com/story/6087721
September 16, 2025 at 10:38 AM
CSL goes all in on VarmX and its coagulation-restoring therapy firstwordpharma.com/story/6087721
📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊
🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need
👉 buff.ly/aO4iHwV
#YsiosPortfolio #vc
🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need
👉 buff.ly/aO4iHwV
#YsiosPortfolio #vc
September 16, 2025 at 10:08 AM
📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊
🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need
👉 buff.ly/aO4iHwV
#YsiosPortfolio #vc
🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need
👉 buff.ly/aO4iHwV
#YsiosPortfolio #vc
🗞️ Bon dia! Us compartim la nostra portada:
👉 “Barcelona ha d’exercir de capital d’un territori vitivinícola ric i divers” (✍️ Ainara Valadez)
👉 La pota barcelonina de la macrooperació biomèdica de VarmX i CSL, valorada en fins a 2.200 milions de dòlars (✍️ Elena Busquets)
👉 “Barcelona ha d’exercir de capital d’un territori vitivinícola ric i divers” (✍️ Ainara Valadez)
👉 La pota barcelonina de la macrooperació biomèdica de VarmX i CSL, valorada en fins a 2.200 milions de dòlars (✍️ Elena Busquets)
September 16, 2025 at 7:00 AM
🗞️ Bon dia! Us compartim la nostra portada:
👉 “Barcelona ha d’exercir de capital d’un territori vitivinícola ric i divers” (✍️ Ainara Valadez)
👉 La pota barcelonina de la macrooperació biomèdica de VarmX i CSL, valorada en fins a 2.200 milions de dòlars (✍️ Elena Busquets)
👉 “Barcelona ha d’exercir de capital d’un territori vitivinícola ric i divers” (✍️ Ainara Valadez)
👉 La pota barcelonina de la macrooperació biomèdica de VarmX i CSL, valorada en fins a 2.200 milions de dòlars (✍️ Elena Busquets)
John Glasspool -- former head of strategy at Baxalta -- takes CEO post at Dutch anticoagulants play VarmX. Most recently, Glasspool was CEO of Blackstone-backed Anthos.
November 13, 2024 at 9:50 PM
John Glasspool -- former head of strategy at Baxalta -- takes CEO post at Dutch anticoagulants play VarmX. Most recently, Glasspool was CEO of Blackstone-backed Anthos.